Compare Crispr Therapeutics AG (CRSP) vs ON Holding AG (ONON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs ON Holding AG — how do they compare? Crispr Therapeutics AG trades at $53.98 (market cap $5.23B), while ON Holding AG trades at $31.07 (market cap $10.33B). The key difference: ON Holding AG is the larger of the two by market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, ON Holding AG nearer its low. Which is the better fit depends on your goals.
| CRSP | ONON | |
|---|---|---|
Market Cap | $5.23B | $10.33B |
Sector | Health | Technology |
52-Week High | $76.78 | $50.63 |
52-Week Low | $44.34 | $30.91 |
Enterprise Value | $3.65B | $9.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
ONON stock is trading at $31.01, down 20.04% after Q2 2026 results showed a revenue miss and lowered full-year growth guidance. The technical picture is bearish with support near $29, while fundamentals reveal strong profitability margins and earnings beats. Analyst sentiment remains largely positive despite the sell-off, with a consensus price target of $52.86.
The outlook is mixed: robust DTC growth and margin expansion offer upside, but wholesale softness and guidance cuts pose near-term risks. Investors face volatility from consumer spending concerns and competitive pressures, though long-term brand momentum supports a growth-at-a-reasonable-price thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
